April 24, 2014 1:19 AM ET

Healthcare Providers and Services

Company Overview of Drug Safety Alliance, Inc.

Company Overview

Drug Safety Alliance, Inc. provides safety and risk management services supporting pharmaceutical, biotech, medical device, consumer health, and animal health organizations globally. It offers full service or tailored pharmacovigilance, database and information technology, and pharmacovigilance consulting services. The company was founded in 2000 and is based in Durham, North Carolina. As of August 28, 2012, Drug Safety Alliance, Inc. operates as a subsidiary of UDG Healthcare plc.

5003 South Miami Boulevard

Suite 500

Durham, NC 27703

United States

Founded in 2000





Key Executives for Drug Safety Alliance, Inc.

Chief Executive Officer
Chief Operating Officer
Chief Strategy and Information Officer
Vice President of Organizational Development & Human Resources
Vice President of Business Development & Marketing
Compensation as of Fiscal Year 2013.

Drug Safety Alliance, Inc. Key Developments

United States Food and Drug Administration Approves Bosulif (Bosutinib) of Drug Safety Alliance, Inc

Drug Safety Alliance, Inc. announced that United States Food and Drug Administration approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults. An estimated 5,430 men and women will be diagnosed with CML in 2012. Most people with CML have a genetic mutation, called the Philadelphia chromosome, which causes the bone marrow to make an enzyme called tyrosine kinase. This enzyme triggers the development of too many abnormal and unhealthy white blood cells called granulocytes. Granulocytes fight infection. Bosulif is intended for patients with chronic, accelerated or blast phase Philadelphia chromosome positive CML who are resistant to or who cannot tolerate other therapies, including imatinib. Bosulif works by blocking the signal of the tyrosine kinase that promotes the development of abnormal and unhealthy granulocytes.

The U.S. Food and Drug Administration Approves Drug Safety Alliance, Inc.'s Lucentis to Treat DME

The U.S. Food and Drug Administration approved Drug Safety Alliance, Inc.'s Lucentis (ranibizumab injection) for the treatment of diabetic macular edema (DME), a sight-threatening eye disease that occurs in people with diabetes.

FDA Approves Drug Safety Alliance, Inc.'s Tudorza Pressair to Treat Chronic Obstructive Pulmonary Disease

The U.S. Food and Drug Administration approved Drug Safety Alliance, Inc.'s Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm (narrowing of the airways in the lung) associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Similar Private Companies By Industry

Company Name Region
Priority Healthcare Corporation United States
Multicare Associates, Inc. United States
Mega Care Inc. United States
Metabolic Solutions, Inc. United States
Miami Kendall FL Endoscopy ASC, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Drug Safety Alliance, Inc., please visit www.drugsafetyalliance.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.